Trovagene announces expansion of key claims for its NPM1 patent portfolio for AML
Trovagene announced the USPTO, and separately, the EPO, have allowed claims for Patent Application 13/959739 and Patent Application EP10184598.0, respectively, entitled "Nucleophosmin Protein Mutants, Corresponding Gene Sequences and Uses Thereof." June 26, 2017